Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

virbac sa - hydrocortisonaceponaat - oorspray, oplossing - hydrocortisonaceponaat 0,584 mg/ml, - hydrocortisone - honden

Europese Unie - Nederlands - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - middelen voor dermatitis, met uitzondering van corticosteroïden - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Europese Unie - Nederlands - EMA (European Medicines Agency)

diurnal europe b.v. - hydrocortison - adrenal hyperplasia, congenital - corticosteroïden voor systemisch gebruik - treatment of congenital adrenal hyperplasia (cah) in adolescents aged 12 years and over and adults.

Europese Unie - Nederlands - EMA (European Medicines Agency)

le vet b.v. - prednisolon - corticosteroïden voor systemisch gebruik, normaal, prednisolone, systemische hormonale preparaten, excl. geslachtshormonen en insuline - paarden - verlichting van inflammatoire en klinische parameters geassocieerd met recidiverende luchtwegobstructie (rao) bij paarden, in combinatie met omgevingscontrole.

Europese Unie - Nederlands - EMA (European Medicines Agency)

dechra regulatory b.v. - betamethasone acetate, terbinafine, florfenicol - corticosteroïden en anti-infectives in combinatie - honden - behandeling van acute otitis externa.

Europese Unie - Nederlands - EMA (European Medicines Agency)

intervet international bv - resocortolbutyraat - corticosteroïden, dermatologische preparaten - honden - behandeling van acute gelokaliseerde vochtige dermatitis.

Europese Unie - Nederlands - EMA (European Medicines Agency)

dechra regulatory b.v. - desoxycortonpivalaat - corticosteroïden voor systemisch gebruik - honden - voor gebruik als vervangende therapie voor mineralocorticoïde tekort bij honden met primaire hypoadrenocorticism (de ziekte van addison).

Europese Unie - Nederlands - EMA (European Medicines Agency)

theravia - dexamethason - multiple myeloma - corticosteroïden voor systemisch gebruik - behandeling van multipel myeloom.

Europese Unie - Nederlands - EMA (European Medicines Agency)

ecuphar - hydrocortisonacceponaat - corticosteroïden, dermatologische preparaten - honden - voor symptomatische behandeling van inflammatoire en pruritische dermatosen bij honden. for alleviation of clinical signs associated with atopic dermatitis in dogs.

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

dexamethasondinatriumfosfaat 1,1 mg/ml samenstelling overeenkomend met ; dexamethasonfosfaat 1 mg/ml - oogdruppels, oplossing - dinatriumedetaat 2-water ; dinatriumwaterstoffosfaat 12-water (e 339) ; natriumchloride ; natriumhydroxide (e 524) ; water voor injectie ; zoutzuur (e 507)